Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04729348 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04729348: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04729348 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04729348, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this research is to examine if an experimental drug combination impacts the survival rate of individuals with Leptomeningeal Metastases This research study involves an experimental drug combination. The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2024-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04729348
The ClinicalTrials.gov registry entry for NCT04729348 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04729348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04729348 about?
NCT04729348 is a clinical study titled "Pembrolizumab And Lenvatinib In Leptomeningeal Metastases". The purpose of this research is to examine if an experimental drug combination impacts the survival rate of individuals with Leptomeningeal Metastases This research study involves an experimental drug combination. The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatin...
What is the current status of trial NCT04729348?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-03-08. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT04729348?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04729348?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.